Brief: Beijing Biostar Pharmaceuticals Sees Net Loss Of RMB146 Mln To RMB151 Mln For Year
25/02/2025 13:33
Feb 25 (Reuters) - Beijing Biostar Pharmaceuticals Co Ltd 2563.HK: SEES NET LOSS RMB146 MILLION TO RMB151 MILLION FOR YEAR EXPECTED RESULT DUE TO INCREASED SALES REVENUE FOR YEAR, OTHERS Further company coverage: 2563.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Beijing Biostar Pharmaceuticals
See all newsBrief: Beijing Biostar Pharmaceuticals To Issue 25 MLN New Shares At HK$4.00 Per Share
Brief: Beijing Biostar Pharmaceuticals Says Board Resolves To Repurchase H Shares In Open Market
Brief: Beijing Biostar Pharmaceuticals Posts FY Loss Attributable RMB131.4 Mln
Brief: FDA Grants Orphan Drug Designation To Biostar Pharma's Utidelone
Brief: Biostar Pharma Doses First Patients In Two Phase II/III Global Trials Of Utidelone Capsule (UTD2) For Cancer